US Funding Cuts And Global Pressures Will Hamper Progress

Key Takeaways

• Uncertain government and academic funding, plus shifting policy priorities, threaten core revenue growth and long-term market potential.
  
• Competitive pressure, high costs, and regulatory risks may erode margins and market share, limiting profitability and earnings recovery.
  
• Growing recurring consumables revenue, expanded market reach through innovation and global diversification, and continued operational efficiency position the company for sustained growth despite macroeconomic challenges.

Catalysts

A life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific.

• Prolonged and escalating uncertainty in U.S. academic and government research funding, compounded by direct NIH funding caps, widespread grant delays, and potential federal budget cuts, raises the risk of a multi-year stagnation or contraction in the company's core U.S. revenue base, which represents nearly half of total sales, jeopardizing growth outlook and top-line expansion.
  
• Intensifying regulatory and geopolitical pressures, including increased government scrutiny over biotechnology data privacy and the threat of further tariffs or trade barriers, could significantly disrupt global market access and supply chains, especially risking the 10 percent of revenue derived from China, and driving both revenue volatility and increased compliance or logistical costs.
  
• As academic and government funding priorities potentially shift away from basic life sciences toward other public policy objectives, the risk of long-term structural headwinds increases, reducing the total addressable market for genomics instruments and consumables and suppressing long-term revenue potential.
  
• High and sustained operational expenses required for product innovation and ongoing legal/litigation risk, including material patent settlements, may erode operating leverage and keep net margins deeply negative, even as revenue struggles and cost-saving measures like the recent 8 percent headcount reduction reach their practical limits.
  
• The rapid commoditization and competitive encroachment in the single-cell and spatial genomics space, coupled with falling instrument average selling prices and pressures from well-capitalized rivals, threaten to drive margin compression and market share loss, constraining both margin recovery and future earnings growth.

10x Genomics Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• This narrative explores a more pessimistic perspective on 10x Genomics compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
• The bearish analysts are assuming 10x Genomics's revenue will grow by 2.7% annually over the next 3 years.
• The bearish analysts are not forecasting that 10x Genomics will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate 10x Genomics's profit margin will increase from -3.5% to the average US Life Sciences industry of 15.6% in 3 years.
• If 10x Genomics's profit margin were to converge on the industry average, you could expect earnings to reach $108.2 million (and earnings per share of $0.78) by about May 2029, up from -$22.7 million today.
• In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 27.3x on those 2029 earnings, up from -114.9x today. This future PE is lower than the current PE for the US Life Sciences industry at 32.1x.
• The bearish analysts expect the number of shares outstanding to grow by 3.1% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.72%, as per the Simply Wall St company report.

Risks

• Robust growth in consumables, particularly Xenium and Chromium reactions, demonstrates resilient core demand and increasing utilization by both early and large customers, supporting recurring revenues and offsetting CapEx-driven instrument sales slowdowns.
  
• Recent and upcoming product launches, such as GEM-X, Visium HD, and Xenium 5K assays, continue to resonate strongly with customers, reinforcing 10x Genomics' technological leadership and expanding its addressable market, which positions the company well for long-term revenue growth.
  
• Structural improvements in global operations, including the successful re-organization of the sales force and direct business models in regions like Japan and APAC, have led to strong double-digit revenue growth in these markets, diversifying revenue streams and reducing reliance on the challenged US academic sector.
  
• Accelerating adoption of single cell and spatial genomics by biopharma and translational research sectors, evidenced by partnerships with prominent organizations and increasing use cases in clinical and drug development, expands 10x Genomics' opportunities beyond academic customers, which may support higher-margin revenue and longer-term growth.
  
• Strategic cost reductions and a strong cash position (over $427 million in cash and equivalents), along with demonstrated ability to further adjust operating expenses, enable continued investment in innovation while protecting margins and supporting financial stability during macroeconomic turbulence.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bearish price target for 10x Genomics is $17.0, which represents up to two standard deviations below the consensus price target of $24.58. This valuation is based on what can be assumed as the expectations of 10x Genomics's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $32.0, and the most bearish reporting a price target of just $17.0.
• In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $692.5 million, earnings will come to $108.2 million, and it would be trading on a PE ratio of 27.3x, assuming you use a discount rate of 7.7%.
• Given the current share price of $20.5, the analyst price target of $17.0 is 20.6% lower. Despite analysts expecting the underlying business to improve, they seem to believe the market's expectations are too high.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.